Navigation Links
GlaxoSmithKline Update: Influenza A (H1N1)
Date:5/1/2009

LONDON and RESEARCH TRIANGLE PARK, N.C., May 1 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) is committed to supporting governments and health authorities around the world to respond to the emergence of the new influenza A (H1N1) strain.

The company has developed a number of potential interventions which it believes may be of value in efforts to reduce the impact and spread of this new influenza virus. These include the antiviral medicine Relenza (zanamivir) and significant vaccine capability and technology, including use of novel adjuvants.

To ensure continuity of supply and manufacture of all its critical medicines and vaccines, GSK has also invoked its own internal pandemic preparedness plan.

Relenza (zanamivir)

GSK has been working with governments to supply Relenza, for use in a pandemic situation, since the global spread of avian influenza (H5N1) which began in 2003. Relenza has typically been used to diversify and add to government stockpiles of Tamiflu (oseltamivir).

Since 2003, Relenza has been supplied to 26 governments for the purposes of pandemic stockpiling and on average the product constituted 13% of these stockpiles. Prior to the recent outbreak, the last significant order for Relenza was for 10.6 million treatment packs, which was delivered to the UK Government in April 2009.

In relation to the new influenza A (H1N1) strain, the WHO reported that the viruses obtained from the recent human cases were sensitive to oseltamivir and zanamivir but resistant to amantadine and remantadine.(1)

GSK has therefore contacted governments around the world to ascertain demand for Relenza, including those countries most affected by the virus, such as Mexico and the USA. As a result, GSK
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company
2. GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
3. IADR and GlaxoSmithKline Consumer Healthcare announce winners of 2009 Innovation in Oral Care Awards
4. GlaxoSmithKline Consumer Healthcare to Reach 85 Percent of the Worlds Smokers with Quit Aids
5. GlaxoSmithKline Consumer Healthcare Helps to Bridge Oral Care Gap in Appalachia
6. Activplant Corporation Announces Global Agreement with GlaxoSmithKline
7. GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
8. GlaxoSmithKlines Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL
9. GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding
10. GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance : – Developing First-in-Class Endosomal TLR Inhibitors for Autoimmune and Inflammatory Diseases –
11. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... TX (PRWEB) August 21, 2014 Improv ... 20 entertained residents with dementia at Silverado Turtle Creek ... Troupe, which consists of entertainers ranging from ages 10 ... time they perform their 40-minute set. The troupe's philosophy ... it universal and allows them to touch audiences regardless ...
(Date:8/21/2014)... THURSDAY, Aug. 21, 2014 (HealthDay News) -- Black mothers ... babies, and here,s one possible reason why: Hospitals in ... nursing than those in areas with more white residents, ... support breast-feeding are much less common in medical centers ... from the U.S. Centers for Disease Control and Prevention ...
(Date:8/21/2014)... Honolulu (PRWEB) August 21, 2014 ... its 10th anniversary and a national voice in ... leaders in health disparities during the 112th National ... , Distinguished honorees included: , John Ruffin, Ph.D, ... Health and Health Disparities, whose life-long career and ...
(Date:8/21/2014)... rural communities do not routinely screen women for ... medical and public health researchers. Rural women who ... if they seek help., "Rural health care providers ... S. McCall-Hosenfeld, a primary care physician and assistant ... State College of Medicine. "However, in rural settings, ...
(Date:8/21/2014)... 2014 The report "Industrial Flue ... Control System (FGD, DeNOx, Particulate Control, Mercury Control) ... Chemical & Others) - Global Trends & Forecasts ... flue gas treatment systems & services market with ... in terms of value. The industrial flue gas ...
Breaking Medicine News(10 mins):Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:W. Montague Cobb/NMA Health Institute Honors Three Outstanding Leaders in Health Disparities 2Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4
... a condition of the skin that affects more than 80 ... While stress has often been cited // as a source ... ,Twenty-two university students participated in this study. Each participant had ... study. Exam sessions are common sources of stress for students. ...
... report more than half a million women in developing countries ... Safe Motherhood and Newborn Health //are intensifying support to countries ... die while giving birth to her child. ,The ... skilled birth attendants who can help a woman give birth ...
... integrate cardiovascular activity into their lives, such as walking, would ... the study researchers surveyed nearly 18,800 women, ages 70 to ... The data show women who walked for at least 1.5 ... than those who walked less than 40 minutes per week. ...
... reduces the risk of recurrence in women with stage I ... ovary). ,About one quarter of all ovarian cancers are ... 85 percent. Most doctors may prefer not to offer chemotherapy ... treated by surgery alone , thus doctors say that giving ...
... room may be the healthiest environment for your child at ... // may put children at risk for leukemia. Researchers ... the circadian rhythm and suppress the production of melatonin. ... to protect DNA from oxidative damage. Once damaged, DNA may ...
... best friend might be able to detect bladder cancer . ... from malignant tumors in urine samples. ,Six dogs ... to discriminate between urine from patients with bladder cancer and ... samples of urine from six control group participants and one ...
Cached Medicine News:Health News:WHO acts to reduce the maternal death toll 2
(Date:8/21/2014)... Aug. 21, 2014 CVS Caremark Corporation (NYSE: ... Reference Yields and consideration payable in connection with its previously ... 7, 2014 for (1) any and all of its 6.250% ... (2) up to a maximum amount of its 6.125% Senior ... Senior Notes due 2017 (collectively, the "Maximum Tender Offer Notes" ...
(Date:8/21/2014)... 21, 2014  Cyberonics, Inc. (NASDAQ: CYBX ) ... Quarterly highlights 1   Operating ... the first quarter of fiscal 2014, and other achievements, include: ... increase of 6.8%; , Strong international net sales of ... basis; , U.S. net product sales reached a new ...
(Date:8/20/2014)...  The National Association of Drug Diversion Investigators ... the real-time, pseudoephedrine (PSE) blocking system in Indiana. The ... (NPLEx), automatically blocks unlawful PSE sales and helps ... make arrests. Data released by NPLEx shows electronic ... the sale of more than 32,105 boxes of medicine ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... 7, 2012  Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, ... dermatology biopharmaceutical company, today announced that its ... for on-demand viewing. LINK:  ... now" button Provectus Pharmaceuticals, Inc,s ...
... May 7, 2012 A new analysis concludes that rituximab, ... treatment responses lasting at least five years in approximately one ... of bleeding due to chronic immune thrombocytopenic purpura (ITP). In ... Blood , the Journal of the American Society ...
Cached Medicine Technology:Provectus Pharmaceuticals, Inc.'s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com 2Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets 2Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets 3
Single-Piece PMMA Intraocular Lenses....
Single Piece PMMA Lens (Refractive and Bifocal). Anterior chamber Lens....
Hydrophilic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....
STABIBAG Hydrophilic Acrylic Lens....
Medicine Products: